Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Insight Molecular Diagnostics (IMDX) Leases (2020 - 2025)

Insight Molecular Diagnostics' Leases history spans 6 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Leases fell 22.03% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, down 22.03%, while the annual FY2024 figure was $2.8 million, 68.42% up from the prior year.
  • Leases for Q3 2025 was $2.3 million at Insight Molecular Diagnostics, down from $2.5 million in the prior quarter.
  • Across five years, Leases topped out at $4.0 million in Q2 2023 and bottomed at $311000.0 in Q1 2021.
  • The 5-year median for Leases is $2.6 million (2025), against an average of $2.4 million.
  • The largest annual shift saw Leases crashed 90.83% in 2021 before it surged 1025.08% in 2022.
  • A 5-year view of Leases shows it stood at $3.5 million in 2021, then crashed by 37.73% to $2.2 million in 2022, then dropped by 24.87% to $1.6 million in 2023, then surged by 68.42% to $2.8 million in 2024, then fell by 15.13% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Leases are $2.3 million (Q3 2025), $2.5 million (Q2 2025), and $2.6 million (Q1 2025).